In addition, fisetin treatment reversed 12-O-tetradecanoylphorbol-13-acetate (TPA) mediated cell migration in MCF-7 human breast cancer cells, which caused NF-κB inactivation and downregulation of MMP-9 expression [137]. Here, MMP9 is linked to breast carcinoma.